Gliolan

Country: European Union

Language: Maltese

Source: EMA (European Medicines Agency)

Active ingredient:

Idroklorur ta 'l-aċidu 5-aminolevuliniku

Available from:

Photonamic GmbH & Co. KG

ATC code:

L01XD04

INN (International Name):

5-aminolevulinic acid hydrochloride

Therapeutic group:

Aġenti antineoplastiċi

Therapeutic area:

Glioma

Therapeutic indications:

Gliolan huwa indikat f'pazjenti adulti għall-viżwalizzazzjoni ta 'tessut malinn waqt il-kirurġija għal glijoma malinna (l-Organizzazzjoni Dinjija tas-Saħħa grad III u IV).

Product summary:

Revision: 8

Authorization status:

Awtorizzat

Authorization date:

2007-09-07

Patient Information leaflet

                                20
B. FULJETT TA’ TAGĦRIF
20
FULJETT TA’ TAGĦRIF: INFORMAZZJONI GĦALL-UTENT
GLIOLAN 30 MG/ML TRAB GĦAL SOLUZZJONI ORALI
5-aminolevulinic acid hydrochloride
AQRA SEW DAN IL-FULJETT KOLLU QABEL TIBDA TIEĦU DIN IL-MEDIĊINA
PERESS LI FIH INFORMAZZJONI
IMPORTANTI GĦALIK.
•
Żomm dan il-fuljett. Jista’ jkollok bżonn terġa’ taqrah.
•
Jekk ikollok aktar mistoqsijiet, staqsi lit-tabib jew lill-ispiżjar
tiegħek.
•
Jekk ikollok xi effett sekondarju kellem lit-tabib jew lill-ispiżjar
tiegħek. Dan jinkludi xi effett
sekondarju possibbli li mhuwiex elenkat f’dan il-fuljett. Ara
sezzjoni 4.
F’DAN IL-FULJETT:
1.
X’inhu Gliolan u għal xiex jintuża
2.
X’għandek tkun taf qabel ma tieħu Gliolan
3.
Kif għandek tieħu Gliolan
4.
Effetti sekondarji possibbli
5.
Kif taħżen Gliolan
6.
Kontenut tal-pakkett u informazzjoni oħra
1.
X’INHU GLIOLAN U GĦAL XIEX JINTUŻA
Gliolan jintuża għall-viżwalizzazzjoni ta’ ċerti tumuri
tal-moħħ (imsejħa glijomi malinni) matul
kirurġija tat-tumuri.
Gliolan fih sustanza imsejħa aminolevulinic acid (5-ALA). 5-ALA
jakkumula preferibbilment f’ċelloli
ta’ tumuri fejn imbagħad jiġi ttrasformat f’sustanza simili
oħra. Jekk it-tumur imbagħad jitpoġġa taħt
espożizzjoni ta’ dawl blu, din is-sustanza ġdida temetti dawl
aħmar-vjola li jgħin biex wieħed jara
aħjar liema huwa t-tessut normali u liema huwa t-tessut b’tumur.
Dan jgħin lill-kirurgu jneħħi t-tumur
għal kollox filwaqt li jsalva t-tessut b’saħħtu.
2.
X’GĦANDEK TKUN TAF QABEL MA TIEĦU GLIOLAN
TIĦUX GLIOLAN
•
jekk inti allerġiku għal 5-ALA jew porphyrins
•
jekk huwa magħruf jew hemm suspett li għandek tipi akuti jew
kroniċi ta’ porfirja (jiġifieri
disturbi li jintirtu jew jiġu akkwiżiti ta’ ċerti enzimi
fil-passaġġ tas-sinteżi tal-pigment tad-
demm aħmar).
•
jekk taf jew tissuspetta li inti tqila.
TWISSIJIET U PREKAWZJONIJIET
Kellem lit-tabib jew lill-ispiżjar tiegħek qabel tieħu Gliolan.
•
Wara 24 siegħa mill- l-għoti ta’ din il-mediċ
                                
                                Read the complete document
                                
                            

Summary of Product characteristics

                                20
ANNESS I
SOMMARJU TAL-KARATTERISTIĊI TAL-PRODOTT
20
1.
ISEM IL-PRODOTT MEDIĊINALI
Gliolan 30 mg/ml trab għal soluzzjoni orali.
2.
GĦAMLA KWALITATTIVA U KWANTITATTIVA
_ _
Flixkun wieħed fih 1.17 g ta’ 5-aminolevulinic acid (5-ALA), li
jikkorrispondi għal 1.5 g ta’
5-aminolevulinic acid hydrochloride (5-ALA HCl).
1 ml ta’ soluzzjoni rikostitwita fih 23.4 mg ta’ 5-ALA, li
jikkorrispondu għal 30 mg 5-ALA HCl).
3.
GĦAMLA FARMAĊEWTIKA
Trab għal soluzzjoni orali.
It-trab huwa kejk abjad għal offwajt.
4.
TAGĦRIF KLINIKU
4.1
INDIKAZZJONIJIET TERAPEWTIĊI
Gliolan huwa indikat f’adulti għall-wiri ta’ tessut malinn waqt
operazzjoni għal glijoma malinna
(WHO grad III u IV).
4.2
POŻOLOĠIJA U METODU TA’ KIF GĦANDU JINGĦATA
Dan il-prodott mediċinali għandu jintuża biss minn newrokirurgi
ta’ esperjenza familjari mal-kirurġija
ta’ glijomi malinni u għarfien profond tal-anatomija funzjonali
tal-moħħ li jkunu temmew b’suċċess
kors fil-kirurġija iggwidata bil-fluworexxenza.
Pożoloġija
Id-doża rakkomandata hija ta’ 20 mg ta’ 5-ALA HCl għal kull
kilogramm ta’ piż tal-ġisem.
In-numru totali ta’ fliexken meħtieġa biex tinkiseb id-doża
maħsuba għall-pazjent individwali jistgħu
jiġu determinati skont l-ekwazzjoni t’hawn taħt (miżjuda jew
imnaqqsa sal-eqreb flixkun sħiħ):
_ _
_Piż tal-ġisem tal-pazjent (kg) _
_Numru ta’ fliexken = _
_——————————————— _
_ _
_75 kg/flixkun _
Il-volum tal-għoti meħtieġ biex tinkiseb id-doża maħsuba
għall-pazjent individwali jista’ jiġi kkalkulat
skont l-ekwazzjoni t’hawn taħt:
_ _
_Piż tal-ġisem tal-pazjent (kg) x 20 mg/kg _
_Volume tal-għoti (ml) = _
_———————————————————_
_ _
_ _
_30 mg/ml _
_Indeboliment tal-kliewi jew tal-fwied _
Ma sarux provi fuq pazjenti b’indeboliment klinikament rilevanti
tal-fwied jew tal-kliewi. Għalhekk,
dan il-prodott mediċinali għandu jintuża b’kawtela f’tali
pazjenti.
_Anzjani_
M’hemm l-ebda struzzjonijiet 
                                
                                Read the complete document
                                
                            

Documents in other languages

Patient Information leaflet Patient Information leaflet Bulgarian 28-04-2023
Summary of Product characteristics Summary of Product characteristics Bulgarian 28-04-2023
Public Assessment Report Public Assessment Report Bulgarian 24-09-2007
Patient Information leaflet Patient Information leaflet Spanish 28-04-2023
Public Assessment Report Public Assessment Report Spanish 24-09-2007
Patient Information leaflet Patient Information leaflet Czech 28-04-2023
Public Assessment Report Public Assessment Report Czech 24-09-2007
Patient Information leaflet Patient Information leaflet Danish 28-04-2023
Public Assessment Report Public Assessment Report Danish 24-09-2007
Patient Information leaflet Patient Information leaflet German 28-04-2023
Public Assessment Report Public Assessment Report German 24-09-2007
Patient Information leaflet Patient Information leaflet Estonian 28-04-2023
Public Assessment Report Public Assessment Report Estonian 24-09-2007
Patient Information leaflet Patient Information leaflet Greek 28-04-2023
Public Assessment Report Public Assessment Report Greek 24-09-2007
Patient Information leaflet Patient Information leaflet English 28-04-2023
Public Assessment Report Public Assessment Report English 24-09-2007
Patient Information leaflet Patient Information leaflet French 28-04-2023
Public Assessment Report Public Assessment Report French 24-09-2007
Patient Information leaflet Patient Information leaflet Italian 28-04-2023
Public Assessment Report Public Assessment Report Italian 24-09-2007
Patient Information leaflet Patient Information leaflet Latvian 28-04-2023
Public Assessment Report Public Assessment Report Latvian 24-09-2007
Patient Information leaflet Patient Information leaflet Lithuanian 28-04-2023
Summary of Product characteristics Summary of Product characteristics Lithuanian 28-04-2023
Public Assessment Report Public Assessment Report Lithuanian 24-09-2007
Patient Information leaflet Patient Information leaflet Hungarian 28-04-2023
Summary of Product characteristics Summary of Product characteristics Hungarian 28-04-2023
Public Assessment Report Public Assessment Report Hungarian 24-09-2007
Patient Information leaflet Patient Information leaflet Dutch 28-04-2023
Public Assessment Report Public Assessment Report Dutch 24-09-2007
Patient Information leaflet Patient Information leaflet Polish 28-04-2023
Public Assessment Report Public Assessment Report Polish 24-09-2007
Patient Information leaflet Patient Information leaflet Portuguese 28-04-2023
Summary of Product characteristics Summary of Product characteristics Portuguese 28-04-2023
Public Assessment Report Public Assessment Report Portuguese 24-09-2007
Patient Information leaflet Patient Information leaflet Romanian 28-04-2023
Public Assessment Report Public Assessment Report Romanian 24-09-2007
Patient Information leaflet Patient Information leaflet Slovak 28-04-2023
Public Assessment Report Public Assessment Report Slovak 24-09-2007
Patient Information leaflet Patient Information leaflet Slovenian 28-04-2023
Summary of Product characteristics Summary of Product characteristics Slovenian 28-04-2023
Public Assessment Report Public Assessment Report Slovenian 24-09-2007
Patient Information leaflet Patient Information leaflet Finnish 28-04-2023
Public Assessment Report Public Assessment Report Finnish 24-09-2007
Patient Information leaflet Patient Information leaflet Swedish 28-04-2023
Public Assessment Report Public Assessment Report Swedish 24-09-2007
Patient Information leaflet Patient Information leaflet Norwegian 28-04-2023
Summary of Product characteristics Summary of Product characteristics Norwegian 28-04-2023
Patient Information leaflet Patient Information leaflet Icelandic 28-04-2023
Summary of Product characteristics Summary of Product characteristics Icelandic 28-04-2023
Patient Information leaflet Patient Information leaflet Croatian 28-04-2023

View documents history